BeOne Medicines Ltd. (ONC)
350.84
-2.62
(-0.74%)
USD |
NASDAQ |
Sep 18, 16:00
350.83
-0.01
(0.00%)
After-Hours: 20:00
BeOne Medicines Cash from Operations (Quarterly) : 463.60M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 463.60M |
| March 31, 2026 | 201.94M |
| December 31, 2025 | 418.93M |
| September 30, 2025 | 403.20M |
| June 30, 2025 | 264.35M |
| March 31, 2025 | 44.08M |
| December 31, 2024 | 75.16M |
| September 30, 2024 | 188.37M |
| June 30, 2024 | -95.59M |
| March 31, 2024 | -308.57M |
| December 31, 2023 | -221.64M |
| September 30, 2023 | -78.15M |
| June 30, 2023 | -293.89M |
| March 31, 2023 | -563.78M |
| December 31, 2022 | -318.19M |
| September 30, 2022 | -561.91M |
| June 30, 2022 | -378.82M |
| March 31, 2022 | -236.89M |
| December 31, 2021 | -507.70M |
| September 30, 2021 | -497.58M |
| June 30, 2021 | -420.27M |
| March 31, 2021 | 125.10M |
| Date | Value |
|---|---|
| December 31, 2020 | -332.33M |
| September 30, 2020 | -346.24M |
| June 30, 2020 | -262.94M |
| March 31, 2020 | -341.94M |
| December 31, 2019 | -267.18M |
| September 30, 2019 | -265.01M |
| June 30, 2019 | -46.10M |
| March 31, 2019 | -171.98M |
| December 31, 2018 | -193.89M |
| September 30, 2018 | -132.18M |
| June 30, 2018 | -117.14M |
| March 31, 2018 | -104.50M |
| December 31, 2017 | 93.75M |
| September 30, 2017 | 6.60M |
| June 30, 2017 | -51.89M |
| March 31, 2017 | -35.71M |
| December 31, 2016 | -26.14M |
| September 30, 2016 | -24.28M |
| June 30, 2016 | -19.26M |
| March 31, 2016 | -19.84M |
| December 31, 2015 | -16.76M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | -- |
| CRISPR Therapeutics AG | -83.50M |
| Idorsia Ltd. | -43.01M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -49.41M |
| Cash from Financing (Quarterly) | -6.128M |
| Free Cash Flow | 1.333B |
| Free Cash Flow Per Share (Quarterly) | 3.766 |
| Free Cash Flow to Equity (Quarterly) | 439.88M |
| Free Cash Flow to Firm (Quarterly) | 466.30M |
| Free Cash Flow Yield | 3.29% |